Trial Profile
An Italian, observational, multicenter, retrospective study evaluating efficacy and safety of T-DM1 in heavily pretreated HER2-positive advanced breast cancer patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jan 2018
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium
- 26 Jul 2016 New trial record
- 07 Jun 2016 Results of heavily pretreated patients (n=119) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology